9. The composition of claim 8 wherein said coating comprises methacrylic acid copolymers containing at least 40 % methacrylic acid.

10. The composition of claim 8 wherein said composition is produced in a tablet form.

11. The composition of claim 10, wherein said tablet has a harness between 10 and 70 N.

12. The composition of claim 8 wherein said composition is produced in a granule or pellet form.

13. The composition of claim 12 wherein said granule or pellet is contained in a capsule.

14. The composition of claim 1 wherein said salt is a mono-sodium salt.

15. The composition of claim 14 wherein said salt is in crystalline form.

16. The composition of claim 1 wherein said composition comprises from about 50 mg to 1.5 g of a pharmaceutically acceptable mycophenolate salt.

17. A pharmaceutical composition comprising a mycophenolate mono-sodium salt, the composition being adapted to prevent release mycophenolate in the stomach, wherein said composition has an enteric coating and said enteric coating comprises cellulose acetate phthalate and trimellitate, or methacrylic acid copolymers containing at least 40 % methacrylic acid, or hydroxypropyl methylcellulose phthalate.

18. The composition of claim 17 wherein said mono-sodium salt is in crystalline form.

19. The composition of claim 17 wherein said composition is in a tablet form and said tablet form has a hardness between 10 and 70 N.

20. The composition of claim 17 wherein said composition comprises from about 50 mg to 1.5 g of a pharmaceutically acceptable mycophenolate salt.